The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV
Open accessAbstract
With the current trajectory of the 2019‐nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better‐studied cousin, SARS‐CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA‐dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS‐CoV. Herein, we suggest four potential drug candidates (an ACE2‐based peptide, remdesivir, 3CLpro‐1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019‐nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad‐spectrum anti‐coronaviral agents for future epidemics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,031
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Virus-encoded proteinases and proteolytic processing in the Nidovirales
Ziebuhr, J., Gorbalenya, A. E., & Snijder, E. J. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-4-853 · Cited by 1,029
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
Kirchdoerfer, R. N., & Ward, A. B. (2019) · Nature Communications · doi:10.1038/s41467-019-10280-3 · Cited by 896
Báez-Santos, Y. M., St. John, S. E., & Mesecar, A. D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2014.12.015 · Cited by 854
Protease inhibitors targeting coronavirus and filovirus entry
Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., Barnard, D., Pöhlmann, S., McKerrow, J. H., Renslo, A. R., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.011 · Cited by 583
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444
Cited by
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105924 · Cited by 6,068
Huang, Y., Yang, C., Xu, X.-F., Xu, W., & Liu, S.-W. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0485-4 · Cited by 2,224
COVID-19 outbreak: Migration, effects on society, global environment and prevention
Chakraborty, I., & Maity, P. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138882 · Cited by 1,789
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?
Long, C., Xu, H., Shen, Q., Zhang, X., Fan, B., Wang, C., Zeng, B., Li, Z., Li, X., & Li, H. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.108961 · Cited by 971
Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00489 · Cited by 953
Lai, C.-C., Liu, Y. H., Wang, C.-Y., Wang, Y.-H., Hsueh, S.-C., Yen, M.-Y., Ko, W.-C., & Hsueh, P.-R. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.02.012 · Cited by 935
The SARS-CoV-2 main protease as drug target
Ullrich, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127377 · Cited by 772
The epidemiology and clinical information about COVID-19
Ge, H., Wang, X., Yuan, X., Xiao, G., Wang, C., Deng, T., Yuan, Q., & Xiao, X. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03874-z · Cited by 672
Wu, J., Liu, J., Zhao, X., Liu, C., Wang, W., Wang, D., Xu, W., Zhang, C., Yu, J., Jiang, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa199 · Cited by 626
Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735227 · Cited by 623
Candidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
COVID-19: Disease, management, treatment, and social impact
Ali, I., & Alharbi, O. M. L. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138861 · Cited by 551
Romano, M., Ruggiero, A., Squeglia, F., Maga, G., & Berisio, R. (2020) · Cells · doi:10.3390/cells9051267 · Cited by 527
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.011 · Cited by 488
Yi, C., Sun, X., Ye, J., Ding, L., Liu, M., Yang, Z., Lu, X., Zhang, Y., Ma, L., Gu, W., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0458-z · Cited by 486
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past
Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01949 · Cited by 475
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
Du, Y., & Chen, X. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1844 · Cited by 418
Das, S., Sarmah, S., Lyndem, S., & Singha Roy, A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1763201 · Cited by 380
Stawicki, S., Jeanmonod, R., Miller, A., Paladino, L., Gaieski, D., Yaffee, A., De Wulf, A., Grover, J., Papadimos, T., Bloem, C., et al. (2020) · Journal of Global Infectious Diseases · doi:10.4103/jgid.jgid_86_20 · Cited by 373
Remdesivir as a possible therapeutic option for the COVID-19
Al-Tawfiq, J. A., Al-Homoud, A. H., & Memish, Z. A. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101615 · Cited by 367
A candidate multi-epitope vaccine against SARS-CoV-2
Kar, T., Narsaria, U., Basak, S., Deb, D., Castiglione, F., Mueller, D. M., & Srivastava, A. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-67749-1 · Cited by 349
Structural insights into SARS-CoV-2 proteins
Arya, R., Kumari, S., Pandey, B., Mistry, H., Bihani, S. C., Das, A., Prashar, V., Gupta, G. D., Panicker, L., & Kumar, M. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.11.024 · Cited by 348
Goyal, B., & Goyal, D. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00058 · Cited by 344
Cao, Y.-C., Deng, Q.-X., & Dai, S.-X. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101647 · Cited by 320
Gentile, D., Patamia, V., Scala, A., Sciortino, M. T., Piperno, A., & Rescifina, A. (2020) · Marine Drugs · doi:10.3390/md18040225 · Cited by 319
Arguments in favour of remdesivir for treating SARS-CoV-2 infections
Ko, W.-C., Rolain, J.-M., Lee, N.-Y., Chen, P.-L., Huang, C.-T., Lee, P.-I., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105933 · Cited by 316
Elengoe, A. (2020) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2020.11.3.08 · Cited by 307
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306
The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase
Lung, J., Lin, Y., Yang, Y., Chou, Y., Shu, L., Cheng, Y., Liu, H. T., & Wu, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25761 · Cited by 295
Mirza, M. U., & Froeyen, M. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.04.008 · Cited by 284
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
Liu, T., Luo, S., Libby, P., & Shi, G.-P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107587 · Cited by 273
Abian, O., Ortega-Alarcon, D., Jimenez-Alesanco, A., Ceballos-Laita, L., Vega, S., Reyburn, H. T., Rizzuti, B., & Velazquez-Campoy, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.235 · Cited by 262
Updated Approaches against SARS-CoV-2
Li, H., Zhou, Y., Zhang, M., Wang, H., Zhao, Q., & Liu, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00483-20 · Cited by 258
Freedberg, D. E., Conigliaro, J., Wang, T. C., Tracey, K. J., Callahan, M. V., Abrams, J. A., Sobieszczyk, M. E., Markowitz, D. D., Gupta, A., O’Donnell, M. R., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.053 · Cited by 257
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
A critical overview of computational approaches employed for COVID-19 drug discovery
Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206
A Comprehensive Review About SARS-CoV-2
Haque, S. M., Ashwaq, O., Sarief, A., & Azad John Mohamed, A. K. (2020) · Future Virology · doi:10.2217/fvl-2020-0124 · Cited by 121
Verma, A. K., & Aggarwal, R. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13812 · Cited by 54
Cosolvent and Dynamic Effects in Binding Pocket Search by Docking Simulations
(2021) · doi:10.1021/acs.jcim.1c00924 · Cited by 9
Metadata
- Authors
- Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R.
- Venue
- ChemBioChem
- Publisher
- Wiley
- Published
- 2020-02-25
- Volume
- 21
- Issue
- 5
- Pages
- 730-738
- ISSN
- 1439-4227 (ISSN-L)
- 1439-7633
- OpenAlex
- W3005527412
- Cited by
- 776
- References
- 44
- FWCI
- 20.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.